Identification
- Summary
Cabazitaxel is an antineoplastic agent used for the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
- Brand Names
- Jevtana
- Generic Name
- Cabazitaxel
- DrugBank Accession Number
- DB06772
- Background
Cabazitaxel is an anti-neoplastic used with the steroid medicine prednisone. Cabazitaxel is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2010.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Cabazitaxel (DB06772)
- Weight
- Average: 835.9324
Monoisotopic: 835.377905537 - Chemical Formula
- C45H57NO14
- Synonyms
- Cabazitaxel
- Cabazitaxelum
- External IDs
- RPR-116258A
- RPR116258
- TXD 258
- TXD-258
- TXD258
- XRP 6258
- XRP-6258
- XRP6258
Pharmacology
- Indication
For treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Cabaitaxel has anti-tumour properties and is effective against docetaxel-sensitive and -insensitive tumours.
- Mechanism of action
Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the interference of mitotic and interphase cellular functions. The cell is then unable to progress further into the cell cycle, being stalled at metaphase, thus triggering apoptosis of the cancer cell.
Target Actions Organism ATubulin alpha-4A chain binderHumans ATubulin beta-1 chain binderHumans - Absorption
After an intravenous dose of cabazitaxel 25 mg/m2 every three weeks to a population of 170 patients with solid tumors, the mean Cmax in patients with metastatic prostate cancer was 226 ng/mL (CV 107%) and was reached at the end of the one-hour infusion (Tmax). The mean AUC in patients with metastatic prostate cancer was 991 ng.h/mL (CV 34%). Administration with prednisone or prednisolone do not effect the pharmacokinetic profile of cabazitaxel.
- Volume of distribution
The volume of distribution (Vss) was 4,864 L (2,643 L/m2 for a patient with a median BSA of 1.84 m2) at steady state. Compared to other taxanes, penetrates the CNS to a greater extent.
- Protein binding
Cabazitaxel is mainly bound to human serum albumin (82%) and lipoproteins (88% for HDL, 70% for LDL, and 56% for VLDL).
- Metabolism
Cabazitaxel is extensively metabolized in the liver (>95%), mainly by the CYP3A4/5 isoenzyme (80% to 90%), and to a lesser extent by CYP2C8 which results in 20 different metabolites. Two of these metabolites are active demethylated derivatives of cabaxitaxel and referred to as RPR112698 and RPR123142 respectively. Docetaxel is another metabolite of cabazitaxel. Cabazitaxel is the main circulating moiety in human plasma.
Hover over products below to view reaction partners
- Route of elimination
After a one-hour intravenous infusion [14C]-cabazitaxel 25 mg/m2, approximately 80% of the administered dose was eliminated within 2 weeks. Cabazitaxel is mainly excreted in the feces as numerous metabolites (76% of the dose); while renal excretion of cabazitaxel and metabolites account for 3.7% of the dose (2.3% as unchanged drug in urine).
- Half-life
Following a one-hour intravenous infusion, plasma concentrations of cabazitaxel can be described by a three-compartment pharmacokinetic model with α-, β-, and γ- half-lives of 4 minutes, 2 hours, and 95 hours, respectively.
- Clearance
Cabazitaxel has a plasma clearance of 48.5 L/h (CV 39%; 26.4 L/h/m2 for a patient with a median BSA of 1.84 m2) in patients with metastatic prostate cancer.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Cabazitaxel may cause serious side effects including neutropenia, hypersensitivity reactions, gastrointestinal symptoms, and renal failure. Anticipated complications of overdose include exacerbation of adverse reactions such as bone marrow suppression and gastrointestinal disorders. Cabazitaxel penetrates the blood-brain barrier. LD50, rat = 500 mg/kg
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Cabazitaxel can be increased when it is combined with Abametapir. Abatacept The metabolism of Cabazitaxel can be increased when combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Cabazitaxel. Abemaciclib Cabazitaxel may decrease the excretion rate of Abemaciclib which could result in a higher serum level. Abiraterone The metabolism of Cabazitaxel can be decreased when combined with Abiraterone. Abrocitinib The serum concentration of Cabazitaxel can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Cabazitaxel can be decreased when combined with Acalabrutinib. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cabazitaxel. Acetaminophen The metabolism of Cabazitaxel can be increased when combined with Acetaminophen. Acetazolamide The serum concentration of Cabazitaxel can be increased when it is combined with Acetazolamide. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Avoid grapefruit products. Grapefruit inhibits the CYP3A4 metabolism of cabazitaxel, which may increase its serum concentration.
- Avoid St. John's Wort. This herb induces the CYP3A4 metabolism of cabazitaxel and may reduce its serum concentration.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Cabazitaxel Accord Injection, solution, concentrate 20 mg/ml Intravenous Accord Healthcare S.L.U. 2020-12-23 Not applicable EU 
Cabazitaxel for Injection Solution 60 mg / 6 mL Intravenous Sandoz Canada Incorporated 2019-12-18 Not applicable Canada 
Cabazitaxel for Injection Kit; Solution 40 mg / mL Intravenous Marcan Pharmaceuticals Inc Not applicable Not applicable Canada Cabazitaxel for Injection Solution 45 mg / 4.5 mL Intravenous Sandoz Canada Incorporated 2019-12-18 Not applicable Canada Cabazitaxel for Injection Solution 40 mg / mL Intravenous Dr Reddy's Laboratories Ltd 2020-06-01 Not applicable Canada Jevtana Injection, solution, concentrate 60 mg/1.5ml Intravenous SANOFI WINTHROP INDUSTRIE 2020-12-23 Not applicable EU Jevtana Injection 60 mg/1.5mL Intravenous sanofi-aventis U.S. LLC 2010-06-17 Not applicable US 
Jevtana Solution 40 mg / mL Intravenous Sanofi Aventis 2011-08-23 Not applicable Canada
Categories
- ATC Codes
- L01CD04 — Cabazitaxel
- Drug Categories
- Antineoplastic Agents
- Antineoplastic and Immunomodulating Agents
- BCRP/ABCG2 Inhibitors
- Cardiotoxic antineoplastic agents
- Cyclodecanes
- Cycloparaffins
- Cytochrome P-450 CYP2C8 Substrates
- Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index
- Cytochrome P-450 Substrates
- Diterpenes
- Immunosuppressive Agents
- Microtubule Inhibition
- Microtubule Inhibitors
- Myelosuppressive Agents
- Narrow Therapeutic Index Drugs
- OATP1B1/SLCO1B1 Inhibitors
- OATP1B3 inhibitors
- P-glycoprotein inhibitors
- P-glycoprotein substrates
- P-glycoprotein substrates with a Narrow Therapeutic Index
- Taxane Derivatives
- Taxoids
- Terpenes
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as taxanes and derivatives. These are diterpenoids with a structure based either on the taxane skeleton, or a derivative thereof. In term of phytochemistry, several derivatives of the taxane skeleton exist: 2(3->20)-abeotaxane, 3,11-cyclotaxane, 11(15->1),11(10->9)-abeotaxane, 3,8-seco-taxane, and 11(15->1)-abeotaxane, among others. More complex skeletons have been found recently, which include the taxane-derived [3.3.3] propellane ring system.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Diterpenoids
- Direct Parent
- Taxanes and derivatives
- Alternative Parents
- Benzoic acid esters / Tricarboxylic acids and derivatives / Benzoyl derivatives / Fatty acid esters / Monosaccharides / Tertiary alcohols / Carbamate esters / Secondary alcohols / Oxetanes / Carboxylic acid esters show 8 more
- Substituents
- Alcohol / Aromatic heteropolycyclic compound / Benzenoid / Benzoate ester / Benzoic acid or derivatives / Benzoyl / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Carboxylic acid derivative show 22 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- tetracyclic diterpenoid (CHEBI:63584)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 51F690397J
- CAS number
- 183133-96-2
- InChI Key
- BMQGVNUXMIRLCK-OAGWZNDDSA-N
- InChI
- InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
- IUPAC Name
- (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate
- SMILES
- [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C
References
- Synthesis Reference
Nagesh Palepu, "CABAZITAXEL FORMULATIONS AND METHODS OF PREPARING THEREOF." U.S. Patent US20120065255, issued March 15, 2012.
US20120065255- General References
- Galsky MD, Dritselis A, Kirkpatrick P, Oh WK: Cabazitaxel. Nat Rev Drug Discov. 2010 Sep;9(9):677-8. doi: 10.1038/nrd3254. [Article]
- Kort A, Hillebrand MJ, Cirkel GA, Voest EE, Schinkel AH, Rosing H, Schellens JH, Beijnen JH: Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Apr 15;925:117-23. doi: 10.1016/j.jchromb.2013.02.034. Epub 2013 Mar 5. [Article]
- Nightingale G, Ryu J: Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. P T. 2012 Aug;37(8):440-8. [Article]
- External Links
- Human Metabolome Database
- HMDB0015672
- KEGG Drug
- D09755
- PubChem Compound
- 9854073
- PubChem Substance
- 99443289
- ChemSpider
- 8029779
- 996051
- ChEBI
- 63584
- ChEMBL
- CHEMBL1201748
- ZINC
- ZINC000085536932
- PharmGKB
- PA165958401
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Cabazitaxel
- FDA label
- Download (383 KB)
- MSDS
- Download (99.2 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Metastatic Prostate Cancer 2 4 Completed Treatment Prostate Cancer 2 3 Active Not Recruiting Treatment Adenocarcinoma of Prostate / Progression of Prostate Cancer 1 3 Completed Treatment Metastatic Prostate Cancer 2 3 Completed Treatment Neoplasm / Neoplasms of the Prostate 1 3 Completed Treatment Prostate Cancer 3 3 Recruiting Treatment Metastatic Castration-Resistant Prostate Cancer (mCRPC) / Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1 3 Terminated Treatment Castration Resistant Prostate Cancer / Hormone-Refractory Prostate Cancer 1 3 Unknown Status Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 3 Unknown Status Treatment Prostate Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intravenous 60 mg/1.5ml Injection, solution, concentrate Intravenous 20 MG/ML Injection Parenteral 60 MG Injection, solution, concentrate Intravenous Kit; solution Intravenous 40 mg / mL Solution Intravenous 45 mg / 4.5 mL Solution Intravenous 60 mg / 6 mL Injection, solution, concentrate Intravenous 60 mg/1.5ml Injection, solution, concentrate Intravenous 10 MG/ML Injection Intravenous Injection Intravenous 60 mg/1.5mL Injection, solution, concentrate Intravenous; Parenteral 60 mg/1.5ml Solution Intravenous 40 mg / mL Solution, concentrate Intravenous 60 mg Solution Intravenous Injection Parenteral 60 mg/1.5ml Solution Intravenous 60 mg/1.5ml Injection, solution, concentrate Intravenous drip 60 mg/1.5ml Solution Intravenous 60 mg - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5438072 No 1995-08-01 2014-05-22 US US5698582 No 1997-12-16 2012-07-03 US US6372780 No 2002-04-16 2016-03-26 US US6387946 No 2002-05-14 2016-03-26 US US8927592 Yes 2015-01-06 2031-04-27 US US7241907 Yes 2007-07-10 2026-06-10 US US5847170 Yes 1998-12-08 2021-09-26 US US6331635 No 2001-12-18 2016-03-26 US US10583110 No 2020-03-10 2030-10-27 US US10716777 No 2020-07-21 2030-10-27 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00413 mg/mL ALOGPS logP 3.69 ALOGPS logP 4.2 Chemaxon logS -5.3 ALOGPS pKa (Strongest Acidic) 11.96 Chemaxon pKa (Strongest Basic) -3.6 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 10 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 202.45 Å2 Chemaxon Rotatable Bond Count 15 Chemaxon Refractivity 213.4 m3·mol-1 Chemaxon Polarizability 86.25 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9535 Blood Brain Barrier - 0.9825 Caco-2 permeable - 0.7945 P-glycoprotein substrate Substrate 0.8287 P-glycoprotein inhibitor I Inhibitor 0.6646 P-glycoprotein inhibitor II Inhibitor 0.5887 Renal organic cation transporter Non-inhibitor 0.933 CYP450 2C9 substrate Non-substrate 0.8236 CYP450 2D6 substrate Non-substrate 0.882 CYP450 3A4 substrate Substrate 0.7256 CYP450 1A2 substrate Non-inhibitor 0.8197 CYP450 2C9 inhibitor Non-inhibitor 0.8654 CYP450 2D6 inhibitor Non-inhibitor 0.8935 CYP450 2C19 inhibitor Non-inhibitor 0.8429 CYP450 3A4 inhibitor Non-inhibitor 0.6339 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9068 Ames test Non AMES toxic 0.8028 Carcinogenicity Non-carcinogens 0.9264 Biodegradation Not ready biodegradable 0.9926 Rat acute toxicity 2.6378 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9907 hERG inhibition (predictor II) Non-inhibitor 0.7906
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Binder
- General Function
- Structural constituent of cytoskeleton
- Specific Function
- Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
- Gene Name
- TUBA4A
- Uniprot ID
- P68366
- Uniprot Name
- Tubulin alpha-4A chain
- Molecular Weight
- 49923.995 Da
References
- JEVTANA - cabazitaxel [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Binder
- General Function
- Structural constituent of cytoskeleton
- Specific Function
- Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
- Gene Name
- TUBB1
- Uniprot ID
- Q9H4B7
- Uniprot Name
- Tubulin beta-1 chain
- Molecular Weight
- 50326.56 Da
References
- JEVTANA - cabazitaxel [Link]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- JEVTANA - cabazitaxel [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- JEVTANA - cabazitaxel [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
References
- JEVTANA - cabazitaxel [Link]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- Curator comments
- In vitro, cabazitaxel inhibited P-gp; however, the in vivo risk of cabazitaxel inhibiting P-gp is low at the recommended therapeutic dose.
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- JEVTANA - cabazitaxel [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
- Gene Name
- ABCG2
- Uniprot ID
- Q9UNQ0
- Uniprot Name
- ATP-binding cassette sub-family G member 2
- Molecular Weight
- 72313.47 Da
References
- JEVTANA - cabazitaxel [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
- Gene Name
- SLCO1B1
- Uniprot ID
- Q9Y6L6
- Uniprot Name
- Solute carrier organic anion transporter family member 1B1
- Molecular Weight
- 76447.99 Da
References
- JEVTANA - cabazitaxel [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
- Gene Name
- SLCO1B3
- Uniprot ID
- Q9NPD5
- Uniprot Name
- Solute carrier organic anion transporter family member 1B3
- Molecular Weight
- 77402.175 Da
References
- JEVTANA - cabazitaxel [Link]
Drug created at September 14, 2010 16:21 / Updated at June 03, 2023 08:16